Differences in healthcare service utilization in patients with polypharmacy according to their risk level by adjusted morbidity groups: a population-based cross-sectional study
Tóm tắt
Patients with polypharmacy suffer from complex medical conditions involving a large healthcare burden. This study aimed to describe the characteristics and utilization of primary care (PC) and hospital care (HC) and factors associated in chronic patients with polypharmacy, stratifying by adjusted morbidity groups (AMG) risk level, sex and age, and comparing with non-polypharmacy. Cross-sectional study conducted in a Spanish basic healthcare area. Studied patients were those over 18 years with chronic diseases identified by the AMG tool from Madrid electronic clinical record, which was the data source. Sociodemographic, sociofunctional, clinical and healthcare utilization variables were described and compared by risk level, sex, age and having or not polypharmacy. Factors associated with healthcare utilization in polypharmacy patients were determined by a negative binomial regression model. In the area studied, 61.3% patients had chronic diseases, of which 16.9% had polypharmacy vs. 83.1% without polypharmacy. Patients with polypharmacy (vs. non-polypharmacy) mean age was 82.7 (vs. 52.7), 68.9% (vs. 60.7%) were women, and 22.0% (vs. 1.2%) high risk. Their average number of chronic diseases was 4.8 (vs. 2.2), and 95.6% (vs. 56.9%) had multimorbidity. Their mean number of annual healthcare contacts was 30.3 (vs. 10.5), 25.9 (vs. 8.8) with PC and 4.4 (vs. 1.7) with HC. Factors associated with a greater PC utilization in patients with polypharmacy were elevated complexity, high risk level and dysrhythmia. Variables associated with a higher HC utilization were also increased complexity and high risk, in addition to male sex, being in palliative care, having a primary caregiver, suffering from neoplasia (specifically lymphoma or leukaemia) and arthritis, whereas older age and immobilization were negatively associated. Polypharmacy population compared to non-polypharmacy was characterized by a more advanced age, predominance of women, high-risk, complexity, numerous comorbidities, dependency and remarkable healthcare utilization. These findings could help healthcare policy makers to optimize the distribution of resources and professionals within PC and HC systems, aiming for the improvement of polypharmacy management and rational use of medicines while reducing costs attributed to healthcare utilization by these patients.
Tài liệu tham khảo
World Health Organization. Medication Safety in Polypharmacy. WHO/UHC/SD. Geneva: 2019. https://www.who.int/docs/default-source/patient-safety/who-uhc-sds-2019-11-eng.pdf.
Taghy N, Cambon L, Cohen J-M, Dussart C. Failure to reach a consensus in polypharmacy definition: an obstacle to measuring risks and impacts-results of a literature review. Ther Clin Risk Manag. 2020;16:57–73. https://doi.org/10.2147/TCRM.S214187.
Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12:443–52. https://doi.org/10.1007/s41999-021-00479-3.
Hernández-Rodríguez MÁ, Sempere-Verdú E, Vicens-Caldentey C, González-Rubio F, Miguel-García F, Palop-Larrea V, et al. Evolution of polypharmacy in a spanish population (2005–2015): a database study. Pharmacoepidemiol Drug Saf. 2020;29:433–43. https://doi.org/10.1002/pds.4956.
Delara M, Murray L, Jafari B, Bahji A, Goodarzi Z, Kirkham J, et al. Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis. BMC Geriatr. 2022;22:601. https://doi.org/10.1186/s12877-022-03279-x.
Guillot J, Maumus-Robert S, Bezin J. Polypharmacy: a general review of definitions, descriptions and determinants. Therapie. 2020;75:407–16. https://doi.org/10.1016/j.therap.2019.10.001.
Lee ES, Koh HL, Ho EQ-Y, Teo SH, Wong FY, Ryan BL, et al. Systematic review on the instruments used for measuring the association of the level of multimorbidity and clinically important outcomes. BMJ Open. 2021; 11: e041219. https://doi.org/10.1136/bmjopen-2020-041219.
Monterde D, Vela E, Clèries M, Garcia-Eroles L, Roca J, Pérez-Sust P. Multimorbidity as a predictor of health service utilization in primary care: a registry-based study of the Catalan population. BMC Fam Pract. 2020;21:39. https://doi.org/10.1186/s12875-020-01104-1.
Merino-Barbancho B, Arroyo P, Rujas M, Cipric A, Ciccone N, Lupiáñez-Villanueva F, et al. Multi-stakeholder Approach for Designing an AI Model to Predict Treatment Adherence. In: Duffy VG, editor. Digit Hum Model Appl Heal Safety, Ergon Risk Manag, Cham: Springer Nature Switzerland; 2023. p. 260–71. https://doi.org/10.1007/978-3-031-35748-0_19.
Primary Care Assistance Management. Annual activity report of Primary Care Assistance Management Year 2019. Community of Madrid 2020. http://www.madrid.org/bvirtual/BVCM050220.pdf.
Deb P, Norton EC. Modeling health care expenditures and use. Annu Rev Public Health. 2018;39:489–505. https://doi.org/10.1146/annurev-publhealth-040617-013517.
Walckiers D, Van der Heyden J, Tafforeau J. Factors associated with excessive polypharmacy in older people. Arch Public Health. 2015;73:50. https://doi.org/10.1186/s13690-015-0095-7.
Nascimento RCRM do, Álvares J, Guerra AAJ, Gomes IC, Silveira MR, Costa EA, et al. Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System. Rev Saude Publica. 2017;51:19s. https://doi.org/10.11606/S1518-8787.2017051007136.
Ye L, Yang-Huang J, Franse CB, Rukavina T, Vasiljev V, Mattace-Raso F, et al. Factors associated with polypharmacy and the high risk of medication-related problems among older community-dwelling adults in European countries: a longitudinal study. BMC Geriatr. 2022;22:841. https://doi.org/10.1186/s12877-022-03536-z.
Davies LE, Kingston A, Todd A, Hanratty B. Characterising polypharmacy in the very old: findings from the Newcastle 85+ study. PLoS ONE. 2021;16: e0245648. https://doi.org/10.1371/journal.pone.0245648.
Maxwell CJ, Mondor L, Pefoyo Koné AJ, Hogan DB, Wodchis WP. Sex differences in multimorbidity and polypharmacy trends: a repeated cross-sectional study of older adults in Ontario. Canada PLoS One. 2021;16: e0250567. https://doi.org/10.1371/journal.pone.0250567.
Van Wilder L, Devleesschauwer B, Clays E, Pype P, Vandepitte S, De Smedt D. Polypharmacy and health-related quality of life/psychological distress among patients with chronic disease. Prev Chronic Dis. 2022;19:E50. https://doi.org/10.5888/pcd19.220062.
Al-Dahshan A, Al-Kubiasi N, Al-Zaidan M, Saeed W, Kehyayan V, Bougmiza I. Prevalence of polypharmacy and the association with non-communicable diseases in Qatari elderly patients attending primary healthcare centers: a cross-sectional study. PLoS ONE. 2020;15: e0234386. https://doi.org/10.1371/journal.pone.0234386.
Gharekhani A, Somi M, Ostadrahimi A, Hatefi A, Haji Kamanaj A, Hassannezhad S, et al. Prevalence and predicting risk factors of polypharmacy in Azar cohort population. Iran J Pharm Res IJPR. 2022;21: e126922. https://doi.org/10.5812/ijpr-126922.
Company-Sancho MC, González-Chordá VM, Orts-Cortés MI. Variability in healthcare expenditure according to the stratification of adjusted morbidity groups in the Canary islands (Spain). Int J Environ Res Public Health. 2022. https://doi.org/10.3390/ijerph19074219.
Cho HJ, Chae J, Yoon S-H, Kim D-S. Factors related to polypharmacy and hyper-polypharmacy for the elderly: a nationwide cohort study using National Health Insurance data in South Korea. Clin Transl Sci. 2023;16:193–205. https://doi.org/10.1111/cts.13438.
Seixas B V, Freitas GR. 2021. Polypharmacy among older Brazilians: prevalence, factors associated, and sociodemographic disparities (ELSI-Brazil). Pharm Pract. 19: 2168. https://doi.org/10.18549/PharmPract.2021.1.2168.
Tyagi S, Koh V, Koh GC-H, Low LL, Lee ES. Defining and measuring multimorbidity in primary care in Singapore: results of an online Delphi study. PLoS One. 2022;17:e0278559. https://doi.org/10.1371/journal.pone.0278559.
Chang TI, Park H, Kim DW, Jeon EK, Rhee CM, Kalantar-Zadeh K, et al. Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study. Sci Rep. 2020;10:18964. https://doi.org/10.1038/s41598-020-75888-8.
Nitya S, Ramya G, Kiruthika S, Meenakshi R, Devi JN, Suganya G, et al. Drug utilization pattern and factors associated with polypharmacy and excessive polypharmacy in geriatric medical out-patients at a rural health training centre in India. J Fam Med Prim Care. 2021;10:2636–41. https://doi.org/10.4103/jfmpc.jfmpc_2417_20.
Cebrino J, de la Portero Cruz S. Polypharmacy and associated factors: a gender perspective in the elderly Spanish population (2011–2020). Front Pharmacol. 2023;14:1189644. https://doi.org/10.3389/fphar.2023.1189644.
Shin W-Y, Go T-H, Kang DR, Lee SY, Lee W, Kim S, et al. Patterns of patients with polypharmacy in adult population from Korea. Sci Rep. 2022;12:18073. https://doi.org/10.1038/s41598-022-23032-z.
Kardas P, Lichwierowicz A, Urbański F, Chudzyńska E, Czech M, Kardas G. Prevalence of chronic polypharmacy in community-dwelling elderly people in poland: analysis of national real-world database helps to identify high risk group. Front Pharmacol. 2021;12: 739740. https://doi.org/10.3389/fphar.2021.739740.
Madrid Health Service. Annual report of the Madrid Health Service 2015. Madrid: Community of Madrid; 2016. https://gestiona3.madrid.org/bvirtual/BVCM017858.pdf.
de la Díaz-González MC, Nuez-Herrera LE, de la Rosa-Hormiga M, Cabeza-Mora A, Gutiérrez-Barroso J. Situation of the elderly living alone: morbidity and services provided from the field of primary health care of Gran Canaria. Healthc. 2022. https://doi.org/10.3390/healthcare10101861.
O’Caoimh R, Cornally N, Svendrovski A, Weathers E, FitzGerald C, Healy E, et al. Measuring the effect of carers on patients’ risk of adverse healthcare outcomes using the caregiver network score. J Frailty Aging. 2016;5:104–10. https://doi.org/10.14283/jfa.2016.86.
Chu H-Y, Chen C-C, Cheng S-H. Continuity of care, potentially inappropriate medication, and health care outcomes among the elderly: evidence from a longitudinal analysis in Taiwan. Med Care. 2012;50:1002–9. https://doi.org/10.1097/MLR.0b013e31826c870f.
Campins L, Serra-Prat M, Gózalo I, López D, Palomera E, Agustí C, et al. Randomized controlled trial of an intervention to improve drug appropriateness in community-dwelling polymedicated elderly people. Fam Pract. 2017;34:36–42. https://doi.org/10.1093/fampra/cmw073.
O’Regan A, O’Doherty J, O’Connor R, Cullen W, Niranjan V, Glynn L, et al. How do multi-morbidity and polypharmacy affect general practice attendance and referral rates? A retrospective analysis of consultations. PLoS ONE. 2022;17: e0263258. https://doi.org/10.1371/journal.pone.0263258.
Barrio Cortes J, Suárez Fernández C, de Bandeira Oliveira M, Beca Martínez MT, Lozano Hernández C, Del Cura-González I. Health services utilization in primary care in patients with chronic conditions according to risk levels. Rev Esp Salud Publica. 2019;93:1–15.
Barrio-Cortes J, Castaño-Reguillo A, Beca-Martínez MT, Bandeira-de Oliveira M, López-Rodríguez C, Jaime-Sisó MÁ. Chronic diseases in the geriatric population: morbidity and use of primary care services according to risk level. BMC Geriatr. 2021;21:278. https://doi.org/10.1186/s12877-021-02217-7.
Aranda-Lara JM, Acera SM. Incorporation of telephone care into the provision of primary care and its effects on patient health and satisfaction: Proposal. Semergen. 2022;48:129–36. https://doi.org/10.1016/j.semerg.2021.04.009.
Carrier H, Zaytseva A, Bocquier A, Villani P, Fortin M, Verger P. General practitioners’ attitude towards cooperation with other health professionals in managing patients with multimorbidity and polypharmacy: a cross-sectional study. Eur J Gen Pract. 2022;28:109–17. https://doi.org/10.1080/13814788.2022.2044781.
Ministry of Health, Consumer Affairs and Social Welfare. Strategy for Addressing Chronicity in the National Health System . Ministry of Health, Consumer Affairs and Social Welfare 2019. https://www.sanidad.gob.es/areas/calidadAsistencial/estrategias/abordajeCronicidad/docs/Evaluacion_E.Cronicidad_Final_0.3.pdf.
Hossin MZ. The male disadvantage in life expectancy: can we close the gender gap? Int Health. 2021;13:482–4. https://doi.org/10.1093/inthealth/ihaa106.
Cameron KA, Song J, Manheim LM, Dunlop DD. Gender disparities in health and healthcare use among older adults. J Womens Health. 2010;19:1643–50. https://doi.org/10.1089/jwh.2009.1701.
Jungo KT, Streit S, Lauffenburger JC. Utilization and spending on potentially inappropriate medications by US older adults with multiple chronic conditions using multiple medications. Arch Gerontol Geriatr. 2021;93: 104326. https://doi.org/10.1016/j.archger.2020.104326.
Bhat A, Khanna S, Chen HHL, Gupta A, Gan GCH, Denniss AR, et al. Integrated care in atrial fibrillation: a road map to the future. Circ Cardiovasc Qual Outcomes. 2021;14: e007411. https://doi.org/10.1161/CIRCOUTCOMES.120.007411.
Li J-W, Hsieh H-M, Weng S-F, Lee I-C. Polypharmacy and utilization of health care services: a cohort study of people aged over 50 years in Taiwan. Asia-Pacific J Public Heal. 2019;31:257–66. https://doi.org/10.1177/1010539519828077.
Li C, Zhou R, Yao N, Cornwell T, Wang S. Health care utilization and unmet needs in Chinese older adults with multimorbidity and functional impairment. J Am Med Dir Assoc. 2020;21:806–10. https://doi.org/10.1016/j.jamda.2020.02.010.
Tillmann BW, Fu L, Hill AD, Scales DC, Fowler RA, Cuthbertson BH, et al. Acute healthcare resource utilization by age: a cohort study. PLoS ONE. 2021;16: e0251877. https://doi.org/10.1371/journal.pone.0251877.
Amjad H, Mulcahy J, Kasper JD, Burgdorf J, Roth DL, Covinsky K, et al. Do caregiving factors affect hospitalization risk among disabled older adults? J Am Geriatr Soc. 2021;69:129–39. https://doi.org/10.1111/jgs.16817.
Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12:1249–57. https://doi.org/10.1016/S1470-2045(11)70040-7.
Seoane-Mato D, Sánchez-Piedra C, Silva-Fernández L, Sivera F, Blanco FJ, Pérez Ruiz F, et al. Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): aims and methodology. Reumatol Clin. 2019;15:90–6. https://doi.org/10.1016/j.reuma.2017.06.009.